Drugs / TT-702
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05272709 | Jan 2022 → Jun 2027 expected | cancer | Cancer Research UK | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05272709 ↗ |
| Action | Inhibit | “TT-702 is converted into TT-478, which then targets and blocks the function of the 'A2B adenosine receptor'.” NCT05272709 ↗ |
| Modality | Small molecule | “TT-702 is a 'small molecule prodrug'.” NCT05272709 ↗ |
| Route | Oral | “TT-702 will be administered orally, once daily, for up to 12 months.” NCT05272709 ↗ |